A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell LymphomaWon-Seog Kim, Jun Zhu, Jae‐Yong Kwak et al.|Blood|2020Cited by 4
Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell LymphomaYuqin Song, Junyong Zhu, Won-Seog Kim et al.|Blood|2022Cited by 0